First Intradermal Influenza Vaccine Approved in the European Union
Sanofi Pasteur (Lyon, France), the vaccines division of the Sanofi-Aventis Group, has received marketing authorization from the European Commission for the first intradermal (ID) influenza vaccine using BD Soluvia microinjection system developed by BD (Franklin Lakes, NJ).
Sanofi Pasteur (Lyon, France), the vaccines division of the Sanofi-Aventis Group, has received marketing authorization from the European Commission for the first intradermal (ID) influenza vaccine using BD Soluvia microinjection system developed by BD (Franklin Lakes, NJ).
While most vaccines are injected into the muscle, the microinjection system, called “BD Soluvia” allows accurate vaccine delivery to the dermal layer of the skin using a 1.5-mm microneedle with a 0.1-mL injected volume.
The approval of the first ID microinjection influenza vaccine follows the favorable evaluation from the European Medicines Agency (EMEA) in December 2008 based on the review of data from clinical trials conducted by Sanofi Pasteur. These trials evaluated the safety and effectiveness of the ID influenza vaccine to generate an immune response. The BD microneedle has been shown to be intuitive for caregivers to use and the needle penetration barely perceptible by patients.
As a prefillable delivery device, the microinjection system also provides a high level of sterility assurance and reduced risks associated with vaccine preparation and administration.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
